QUIDEL CORPORATION (NASDAQ:QDEL) Files An 8-K Results of Operations and Financial ConditionItem 2.02Results of Operations and Financial Condition.
On July26, 2017, Quidel Corporation issued a press release announcing the financial results for its second quarter and six months ended June30, 2017 and will hold an earnings conference call at 2:00p.m., Pacific Time, on July26, 2017 to discuss such results. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K.
The information in this current report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section. The information in this current report on Form 8-K shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits.
|
(d)Exhibits. |
|
|
The following exhibit is furnished with this current report on Form 8-K: |
|
|
Exhibit Number |
Description of Exhibit |
|
99.1 |
Press release, dated July26, 2017, reporting Quidel Corporation's financial results for its second quarter and six months ended June30, 2017. |
QUIDEL CORP /DE/ ExhibitEX-99.1 2 qdel-20170630exhibit991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 Quidel Contact: Media and Investors Contact:Quidel Corporation Quidel CorporationRandy Steward Ruben ArguetaChief Financial Officer 858.646.8023858.552.7931 [email protected] QUIDEL REPORTS SECOND QUARTER 2017 FINANCIAL RESULTSSAN DIEGO,…To view the full exhibit click here
About QUIDEL CORPORATION (NASDAQ:QDEL)
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The Company’s diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors and a direct sales force. Internationally, it sells and markets primarily through distributor arrangements. Its diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions, including autoimmune diseases, bone health and thyroid diseases. It provides diagnostic testing solutions under various brand names, including Quidel, QuickVue+ and Thyretain. QUIDEL CORPORATION (NASDAQ:QDEL) Recent Trading Information
QUIDEL CORPORATION (NASDAQ:QDEL) closed its last trading session down -0.25 at 37.30 with 510,756 shares trading hands.
